Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FAZJX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $39,559
Award facts
- Contract value 100% obligated
- $39,559.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at approximately $39.6K by the Defense Logistics Agency on August 7, 2025, for the supply of Entyvio 300 mg vials. The contract, which carries no set-aside designation, is scheduled for completion by August 28, 2025, with performance to be executed at the awardee's Park Ridge location. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500M single-award vehicle valid through November 2026 that enables the agency to procure a comprehensive portfolio of pharmaceutical products supporting military healthcare facilities worldwide.
Entyvio is a biologic medication used in the treatment of inflammatory bowel disease, representing the type of specialty pharmaceutical products that characterize DMS Pharmaceutical Group's federal supply chain role. The company's established presence as a DLA pharmaceutical supplier, combined with its woman-owned small business status, has positioned it as a consistent provider of branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. This award reflects the ongoing operational requirements of the military medical supply system and DMS Pharmaceutical Group's capability to fulfill specialized pharmaceutical delivery needs across the federal sector.
Quick answers
Who was awarded contract SPE2DB25FAZJX?
SPE2DB25FAZJX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 7, 2025.
How much is contract SPE2DB25FAZJX worth?
The government has obligated $39,559 on SPE2DB25FAZJX.
Is contract SPE2DB25FAZJX an order under another contract?
Yes. SPE2DB25FAZJX is a delivery order under SPE2DB24D9222, an indefinite delivery contract.
Was contract SPE2DB25FAZJX competed?
The extent of competition for SPE2DB25FAZJX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award